LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease

The article announces Japan's first and only anti-amyloid Alzheimer's treatment enabling at-home administration. The development could improve treatment convenience for patients with progressive Alzheimer's disease, though no company, clinical data, pricing, sales outlook, or regulatory details were provided.